July 30, 2021 08:49 AM EDT

Biogen launches Phase IV trial to see just how well Aduhelm works in the real world

Nicole DeFeudis

Editor

It could be years before Biogen wraps up its confirmatory trial for its controversial new Alzheimer’s drug Aduhelm (up to nine years, to be precise) …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen launches Phase IV trial to see just how well Aduhelm works in the real world

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Bio­gen launch­es Phase IV tri­al to see just how well Aduhelm works in the re­al world

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Biogen launches Phase IV trial to see just how well Aduhelm works in the real world